Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT-R: PSMA-PET and ctDNA in Prostate Cancer Treated With Radiotherapy
NCT07210086Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2025
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial in prostate cancer (PCa) (3 arms), sponsored by City of Hope. Primary endpoint: Early progressive disease on PSMA-PET prior to PSA-progression up to 5 years. Started Nov 2025; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07210086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210086.